What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Strength:20 mg/mL. Route of administration: IV infusion. Treatment duration: QW for 6 weeks, then at the same dose Q2W up to Week 12. If treatment continues after Week 12, dosing will occur monthly for up to a maximum treatment duration of 6 months.”In the company’s words, NCT07946549 on ClinicalTrials.gov
- Tested for
- Chronic Immune Thrombocytopenia (2 trials), Antibody Mediated Rejection
- Main trialPhase 2
- “The goal of the global Phase 1/2 clinical trial is to evaluate whether CID-103, a novel anti-CD38 monoclonal antibody, is safe and effective in adults with chronic immune thrombocytopenia (ITP). The main questions the study aims to answer are: * To evaluate the safety and tolerability of CID-103 in subjects with ITP with different increasing doses of CID-103. * To further evaluate the safety and tolerability of CID-103 at two or three dose levels and to select an optimal dose and administration regimen for CID-103 for further study of clinical efficacy. The study will be done in two parts:…”In the company’s words, NCT07946549 on ClinicalTrials.gov
Other drugs for Chronic Immune Thrombocytopenia
- RilzabrutinibSanofi · Phase 3
- Human immunoglobulinGrand Shuyang Life Sciences (Chengdu) Co., Ltd. · Phase 3
- Kedrion IVIG 10%Kedrion S.p.A. · Phase 3
- TAK-755Takeda · Phase 3
- TQB3473Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- Efgartigimodargenx · Phase 3
Coming up2
- 30 Nov 2028Phase 2 trial completes · ClinicalTrials.gov
- May 2030Phase 1/2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 18 NovNew trial: none to Phase 2 · ClinicalTrials.gov NCT07946549
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 30 Nov 2028 | A Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia | |
| Phase 1/2Recruiting | 1 Jun 2026 | A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia | |
| Phase 1/2Recruiting | May 2030 | A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR). | |
| Phase 1Completed | 19 Jan 2023 | CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026